Author

C. Schölz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Zutz· 2 shared L. Chen· 2 shared C. Choudhary· 1 shared F. Sippl· 1 shared H. Blum· 1 shared J. Philippou-Massier· 1 shared O. T. Keppler· 1 shared T. Liebner· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Zutz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic compound screening uncovers small molecules for re-activation of latent HIV-1

A. Zutz, L. Chen, F. Sippl, C. Schölz

This study screens epigenetic compounds to identify new latency reversing agents (LRAs) for reactivating latent HIV-1, finding two novel compounds with high reactivation efficiency and low toxicity.

bioRxiv · Aug 21, 2020Pharmacology & Toxicology

Histone deacetylase inhibitors butyrate and bufexamac inhibit de novo HIV-1 infection in CD4 T-cells

C. Schölz, L. Chen, A. Zutz, O. T. Keppler, J. Philippou-Massier, H. Blum, T. Liebner, C. Choudhary

This study shows that HDAC inhibitors butyrate and bufexamac inhibit de novo HIV-1 infection in CD4 T-cells without reactivating latent virus.

bioRxiv · Apr 29, 2020 · PreprintMicrobiology